Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Brian Hoeynck, Shakthi Bhaskar, Andrew P Jallouk, Bhagirathbhai Dholaria, Bipin N. Savani, Olalekan O. Oluwole, David Morgan, Salyka M. Sengsayadeth, Adetola A. Kassim, Vivek Patel

Blood (2024) 144 (Supplement 1): 3663.

https://doi.org/10.1182/blood-2024-211286

Published: 2024

Journal Articles

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Vivek Patel, Katherine Baker, Danielle Fishman, Spencer Lessans, Trent Morris, Bhagirathbhai Dholaria, Reena Jayani, Adetola A. Kassim, Tae Kon Kim, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Salyka M. Sengsayadeth, Shakthi Bhaskar

Blood (2023) 142 (Supplement 1): 5080.

https://doi.org/10.1182/blood-2023-189084

Published: 2023

Journal Articles

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Shakthi Bhaskar, Katherine Baker, Danielle Fishman, Spencer Lessans, Bhagirathbhai Dholaria, Reena Jayani, Adetola A. Kassim, Tae Kon Kim, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Salyka Sengsayadeth, Vivek Patel

Blood (2023) 142 (Supplement 1): 6940.

https://doi.org/10.1182/blood-2023-186217

Published: 2023

Journal Articles

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Naimisha Marneni, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Eden Ayele Biltibo, Vivek Patel, Shakthi Bhaskar, Reena Jayani, Jill Gilbert, Jordan Berlin, Ashwin Kishtagari, Sanjay Mohan, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Adetola A. Kassim, Muhamed Baljevic

Blood (2023) 142 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2023-190749

Published: 2023

Journal Articles

Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort

Tarsheen Sethi, MD MBBS, Alexandra E. Kovach, MD, Emily F Mason, MD PhD, Heidi Chen, PhD, Tamara Moyo, MD PhD, Olalekan O. Oluwole, MBBS, MPH, David Morgan, MD, Nishitha Reddy, MD

Blood (2019) 134 (Supplement_1): 4100.

https://doi.org/10.1182/blood-2019-129634

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 402.

https://doi.org/10.1182/blood-2018-99-111163

Published: 2018

Journal Articles

Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)

Fangxin Hong, PhD, Gita Thanarajasingam, MD, Stephen M. Ansell, MD PhD, Richard F Ambinder, MD, Jonathon B. Cohen, MDMS, Michael Robertson, MD, Kevin A. David, MD, Ranjana H Advani, MD, Timothy S. Fenske, MD, Stefan Klaus Barta, MDMRCP,MS, Neil Palmisiano, MD, Jakub Svoboda, MD, David Morgan, MD, Reem Karmali, MD, Thomas E. Witzig, MD, Amylou C. Dueck, PhD, Paul Novotny, Brad S Kahl, MD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 623.

https://doi.org/10.1182/blood-2018-99-119372

Published: 2018

Journal Articles

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)

Catherine Diefenbach, MD, Fangxin Hong, PhD, Richard F Ambinder, MD, Jonathon B. Cohen, MDMS, Michael Robertson, MD, Kevin A. David, MD, Ranjana H. Advani, MD, Timothy S. Fenske, MD, Stefan Klaus Barta, MDMRCP,MS, Neil Palmisano, MD, Jakub Svoboda, MD, David Morgan, MD, Reem Karmali, MD, Brad S Kahl, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 679.

https://doi.org/10.1182/blood-2018-99-115390

Published: 2018

Journal Articles

Incidence of Central Nervous System (CNS) Relapse in MYC Rearranged Diffuse Large B-Cell Lymphoma: Does CNS Prophylaxis Improve Outcome?

Tarsheen Sethi, MD MBBS, Alexandra E. Kovach, MD, David Morgan, MD, John P. Greer, MD, Nishitha Reddy, MD MSCI, MBBS

Blood (2017) 130 (Supplement 1): 4152.

https://doi.org/10.1182/blood.V130.Suppl_1.4152.4152

Published: 2017

Journal Articles

Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP Therapy

Scott F Huntington, MD, Mahsa Sharifi, PhD, PharmD, John P Greer, MD, David Morgan, MD, Nishitha Reddy, MD

Blood (2010) 116 (21): 1778.

https://doi.org/10.1182/blood.V116.21.1778.1778

Published: 2010

Journal Articles

Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome.

Daniel G Stover, MD, Vishruth K Reddy, John P. Greer, MD, Madan Jagasia, MD, MS, David Morgan, MD, Brian Engelhardt, MD, Adetola A. Kassim, MD, MS, Stacey Goodman, MD, Carole Hunt, Friedrich Schuening, MD, Bipin N. Savani, MD, Nishitha Reddy, MD

Blood (2009) 114 (22): 3407.

https://doi.org/10.1182/blood.V114.22.3407.3407

Published: 2009

Journal Articles

Nucleated Cell (NC) Dose of Autologous (Auto) Marrow Graft Is Not Predictive of Engraftment after Auto-Bone Marrow Transplant (auto-BMT) Following Failed Peripheral Blood Stem Cell (PBSC) Mobilization.

Stephen A. Strickland, MD, Heidi Chen, PhD, Carole Hunt, RN, Wichai Chinratanalab, MD, Brian Engelhardt, MD, Stacey A. Goodman, MD, John P. Greer, MD, Adetola A. Kassim, MD, David Morgan, MD, Katherine L. Ruffner, MD, Friedrich Schuening, MD, Madan Jagasia, MBBS, MS

Blood (2006) 108 (11): 5454.

https://doi.org/10.1182/blood.V108.11.5454.5454

Published: 2006

Journal Articles

Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts

Francisco Arguello, Mark Alexander, Judith A. Sterry, Gabriela Tudor, Erik M. Smith, Naina T. Kalavar, John F. Greene, Jr, William Koss, C. David Morgan, Sherman F. Stinson, Timothy J. Siford, W. Gregory Alvord, Richard L. Klabansky, Edward A. Sausville

Blood (1998) 91 (7): 2482–2490.

https://doi.org/10.1182/blood.V91.7.2482

Published: 1998

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)

Incidence of Central Nervous System (CNS) Relapse in MYC Rearranged Diffuse Large B-Cell Lymphoma: Does CNS Prophylaxis Improve Outcome?

Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP Therapy

Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome.

Nucleated Cell (NC) Dose of Autologous (Auto) Marrow Graft Is Not Predictive of Engraftment after Auto-Bone Marrow Transplant (auto-BMT) Following Failed Peripheral Blood Stem Cell (PBSC) Mobilization.

Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only